08/8/22 – RespireRx Pharmaceuticals Inc. Announces that Sleep Review has Discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 Edition August 8, 2022j3ff1 Read More
05/24/22 – RespireRx Pharmaceuticals Inc. Announces that Dr. Lippa is an Invited Speaker at the 5th International Cannabinoid-Derived Pharmaceuticals Summit May 24, 2022j3ff1 Read More
5/17/22 – RespireRx Pharmaceuticals Inc. Announces RespireRx Presentation at 2022 GRI Virtual Conference presented by CureGRIN and GRIN Therapeutics May 17, 2022j3ff1 Read More
5/16/22 – RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAkine Neuromodulators for the Treatment of Tinnitus May 16, 2022j3ff1 Read More
3/29/22 – WATCH: RespireRx Interim CEO Discusses Provisional Application for a Novel Lipid-Based Formulation Technology (LFT) March 29, 2022j3ff1 Read More
3/24/2022 – Media Coverage: RespireRx Pharmaceuticals files provisional patent that may improve solubility of poorly soluble drugs March 24, 2022j3ff1 Read More
3/23/2022 – RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol March 23, 2022j3ff1 Read More
3/16/22 – RespireRx Pharmaceuticals Inc. Announces Discovery of a New GABAkine Neuromodulator that Protects Against Seizures and Lethality March 16, 2022j3ff1 Read More
3/10/22 – Proactive Investors: RespireRx Pharmaceuticals is developing innovative and revolutionary treatments to combat neuronal signaling disorders March 10, 2022j3ff1 Read More
